|
Daily Medical Update
Bradyarrhythmias
Friday, July 03, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Clinical Cardiology (2026) - Meta-analysis
Key Findings
- Across 40 studies with 8290 patients, left bundle branch area pacing reduced QRS duration versus right ventricular pacing by 35.56 ms and improved left ventricular ejection fraction by 3.77%.
- Left bundle branch area pacing also reduced heart failure hospitalization (RR 0.38) and all-cause mortality (RR 0.55) while maintaining comparable procedural safety.
📋 Practice Implication: When permanent pacing is needed for bradyarrhythmias, favor conduction-system pacing over routine right ventricular pacing when anatomy and operator expertise allow.
|
Clinical Cardiology (2026) - Randomized trial
Key Findings
- In 110 patients with vagal bradycardia plus PVCs or PSVT, Ao-SVC ganglionated plexus modification increased mean heart rate (68.58 vs 56.64 bpm) and minimum heart rate (46.20 vs 41.27 bpm) versus control.
- Cardioneuroablation also improved Wenckebach cycle length and corrected sinus node recovery time, and it reduced syncope with greater quality-of-life improvement than conventional ablation alone.
📋 Practice Implication: For selected patients with vagally mediated bradycardia and coexisting tachyarrhythmias, cardioneuroablation can be considered as a pacemaker-sparing interventional option.
|
Pacing and Clinical Electrophysiology (2026) - Systematic review and meta-analysis
Key Findings
- In 800 patients, thermal ablation increased resting heart rate more than pulsed-field ablation, with a mean difference of 7.57 bpm favoring the autonomically sparing profile of pulsed-field ablation.
- Pulsed-field ablation improved preservation of heart rate variability, with SDNN at 12 months around 150 ms versus 115 ms after thermal ablation, while arrhythmia outcomes remained comparable.
📋 Practice Implication: When choosing an atrial fibrillation ablation modality in patients vulnerable to post-procedural autonomic dysfunction or bradyarrhythmia, pulsed-field ablation may offer a safer physiologic profile.
|
Korean Journal of Anesthesiology (2026) - Meta-analysis of randomized trials
Key Findings
- Remimazolam reduced the risk of bradycardia versus propofol during anesthesia induction in hypertensive adults (RR 0.256) and also reduced hypotension (RR 0.711).
- Remimazolam increased minimum mean arterial pressure by 9.023 mmHg and increased minimum heart rate by 7.2 beats/min versus propofol, although trial sequential analysis remained inconclusive.
📋 Practice Implication: If peri-induction bradycardia would be especially problematic, remimazolam is a reasonable alternative to propofol in hypertensive patients, while recognizing the evidence base is still small.
|
Journal of Hypertension (2025) - Meta-analysis of randomized trials
Key Findings
- Across 39,811 patients, intensive systolic blood pressure control reduced stroke (RR 0.81), myocardial infarction (RR 0.83), cardiovascular death (RR 0.73), and all-cause mortality (RR 0.87) versus standard control.
- Bradycardia did not increase significantly with intensive control (RR 1.12), but syncope increased (RR 1.54), indicating that lower targets changed tolerability more than conduction risk.
📋 Practice Implication: Bradycardia alone should not deter intensive blood pressure treatment in appropriate patients, but syncope surveillance becomes more important as targets tighten.
|
|
💡
Summary
Recent bradyarrhythmia literature was led by pacing-strategy and autonomic-modulation studies, with left bundle branch area pacing showing better electrical synchrony, remodeling, and clinical outcomes than right ventricular pacing. Smaller but clinically relevant analyses also suggest that targeted cardioneuroablation, pulsed-field ablation, and remimazolam-based anesthetic strategies may reduce bradycardia-related complications or autonomic disruption, while intensive blood pressure control did not materially increase bradycardia despite more syncope.
|
|